Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Azoxy doai
Reexamination Certificate
2007-08-08
2008-11-18
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Azoxy doai
C514S151000, C514S158000
Reexamination Certificate
active
07452872
ABSTRACT:
A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
REFERENCES:
patent: 5498608 (1996-03-01), Johnson et al.
patent: 5905073 (1999-05-01), Johnson et al.
patent: 6197341 (2001-03-01), Friess et al.
patent: 6231888 (2001-05-01), Lerner et al.
patent: 6583128 (2003-06-01), Ekwuribe et al.
patent: 2006/0223787 (2006-10-01), Devane et al.
Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA); C. De Mey, Br. J. Clin. Pharmac. (1992), 33, 179-182.
FDA Guidance for Industry, Food-effect Bioavailability and Fed Bioequivalence Studies; US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Dec. 2002, BP.
Carol Cronenberger, MS, Ph.D., NDA: 20-610, Submission Date Jun. 23, 1997, Document stamp date: May 19, 1998.
McLachlan et al., (Aust. Prescriber, pp. 40-41, vol. 29, No. 2, Apr. 2006).
Yu, D.K.; Elvin, A.T.; Morrill, B.; Eichmeier, L.S.; Lanman, R.C.; Lanman, M.B.; Giesing, D.H., “Effect of food coadministration on 5-aminosalicyllic acid oral suspension bioavailability,” Clin Pharmacol Ther. Jul. 1990;48 (1):26-33.
De Mey, C. and Meineke, I., “Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA),” Br J Clin Pharmacol. Feb. 1992;33(2):179-82.
Salix Study No. MPPK 1002. “Granulated Mesalamine Food Effect Pk.”.
Lialda Package Insert.
Ryde, E.M. and Ahnfelt, N.O., “The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food,” Eur J Clin Pharmacol. 1988;34(5):481-8.
Klotz, U., “Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid,” Clin Pharmacokinet. Jul.-Aug. 1985;10(4):285-302.
Colazal Package Insert.
Pentasa Summary Basis for Approval.
Asacol Summary Basis for Approval.
Goebell H; Klotz U; Nehlsen B; Layer P, “Oroileal transit of slow release 5-aminosalicylic acid,” Gut, (May 1993) vol. 34, No. 5, pp. 669-675.
Biotech Business “Colazal “Food Effect” Application Granted FDA Approval,” (Nov. 1, 2006) vol. 19, No. 11.
Schellekens R.C.A.; Stuurman F.E.; van der Weert F.H.J.; Kosterink, J.G.W.; Frijlink, H.W., “A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products,” European Journal of Pharmaceutical Sciences, (2007) vol. 30, No. 1, pp. 15-20.
De Vos, M., “Clinical pharmacokinetics of slow release mesalazine,” Clinical Pharmacokinetics, (2000) vol. 39, No. 2, pp. 85-97.
Norlander, B.; Gotthard R.; Strom M., “Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form,” Alimentary Pharmacology and Therapeutics, (1989) vol. 3, No. 4, pp. 333-342.
Wilding, I R; Kenyon, C J; Hooper, G., “Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet,” Alimentary pharmacology & therapeutics, (Feb. 2000) vol. 14, No. 2, pp. 163-169.
Layer, P. H.; Goebell, H.; Keller, J.; Dignass, A.; Klotz, U., “Delivery and fate of oral mesalamine microgranules within the human small intestine,” Gastroenterology, (May 1995) vol. 108, No. 5, pp. 1427-1433.
Wadworth, A N; Fitton, A., “Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease,” Drugs, (Apr. 1991) vol. 41, No. 4, pp. 647-664.
Qureshi, Altamash I.; Cohen, Russell D., “Mesalamine delivery systems: do they really make much difference?” Advanced Drug Delivery Reviews (2005), 57(2), 281-302.
Norlander, B.; Gotthard, R.; Stroem, M., “Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form,” Alimentary Pharmacology and Therapeutics (1989), 3(4), 333-42.
Keller, J.; Goebell H.; Klotz, U.; Layer, P., [Release patterns of 5-aminosalicylic acid in human small intestine: Importance of galenic preparation], Medizinische Klinik, (May 15, 1998) vol. 93, No. 5, pp. 294-299. Language: German (English Abstract and English Translation).
Godde, R., [Bioavailability in mesalazine therapy: Microcapsules to optimize concentrations in the bowel], Krankenhauspharmazie, (1996) vol. 17, No. 3, pp. 99-104. Language: German (English Abstract and English Translation).
Citizens Petition, Salix Pharmeceuticals, Inc.; Apr. 13, 2005, pp. 1-25.
Supplement to Citizen Petition, Salix Pharmaceuticals, Inc.; Jul. 14, 2006; pp. 1-10.
Supplement to Citizen Petition, Salix Pharmeceuticals, Inc.; Nov. 14, 2006; pp. 1-13
Supplement to Citizen Petition, Salix Pharmeceutical, Inc.; Jun. 14, 2007; pp. 1-15.
Supplement to Citizen Petition, Salix Pharmeceuticals, Inc.; Sep. 27, 2007; pp. 1-7.
Response to Citizens Petition; Food and Drug Administration, Dec. 28, 2007; pp. 1-27.
Letter, L. Johnson; Jan. 2001; p. 1.
Pharmacokinetics of Balsalazide Sprinkled on Food or as Intact Capsules Administered Under Fasting ofr Fed Conditions in Healthy Volunteers, W. Forbes et al.; Dec. 1, 2006; pp. 1-3.
Balsalazide Fed v. Fasted Study; L. Johnson; Feb. 3, 2007, pp. 1-20.
Clinical Pharmacology and Biopharmaceutics Review Part 1; Jun. 22, 2000, pp. 1-52.
Clinical Pharmacology and Biopharmaceutics Review Part 2; Jun. 22, 2000, pp. 1-79.
Clinical Pharmacology and Biopharmaceutics Review Part 1; Jun. 22, 2000, pp. 1-131.
Citizens Petition to the FDA, Amendment—Dissolution Supplement, Jun. 14, 2007.
Sleisenger & Fordtrans's Gastrointestinal and Liver Disease, 6th edition, pp. 593-596 (1998).
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Krass Frederick
Packard Benjamin
Salix Pharmaceuticals, Inc.
LandOfFree
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050976